Status:
COMPLETED
CITrate and Evodial for Effective Dialysis (CITED) Study
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It is not known whether the combination of a heparin-grafted membrane plus citrate-containing dialysate is a valid alternative to regional citrate anticoagulation. This is a cross-over non-inferiority...
Detailed Description
Anticoagulation is one of the supporting pillars of chronic hemodialysis (HD) (1). The optimal anticoagulant regimen provides full anticoagulation of the extracorporeal circuit with minimal systemic e...
Eligibility Criteria
Inclusion
- Patients aged over 18 years,
- hemodynamic stability,
- hemoglobin 9 - 12 g/dl.
Exclusion
- Any hemostatic disorder favoring either bleeding or clotting,
- anti-vitamin K treatment,
- risk of bleeding according to the criteria of Swartz (12).
- Treatment with aspirin, dipyridamole or any drugs likely to interfere with platelet aggregation will be registered carefully, but will not be an exclusion criterion.
- All vascular access types (AV-fistula, AV graft, catheter) are allowed. However, only patients with double route vascular access ('bipuncture') will be included in the study.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02281045
Start Date
October 1 2014
End Date
May 1 2015
Last Update
May 13 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaire Ziekenhuizen Leuven
Leuven, Vlaams-Brabant, Belgium, 3000
2
University Hospitals Leuven
Leuven, Belgium, 3000